Dalbavancin hydrochloride is primarily used as an antibiotic to treat bacterial infections, particularly those caused by Gram-positive bacteria. It is highly effective against skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The drug is administered intravenously and is valued for its long half-life, allowing for less frequent dosing compared to other antibiotics. This makes it a convenient option for outpatient treatment, reducing the need for prolonged hospital stays. It is also explored for use in more complex infections, such as bone and joint infections, due to its potent antibacterial activity and favorable safety profile.